07.24.17
Headquarters: Bagsvaerd, Denmark
twitter.com/novonordisk
www.novonordisk.com
Headcount: 42,446
Year Established: 1989
Revenues: $15,841 (flat)
Net Income: $5,375 (+5%)
R&D: $2,064 (+4%)
TOP SELLING DRUGS
Drug | Indication | 2016 Sales | (+/-%) |
Victoza | diabetes | $2,841 | 8% |
NovoRapid | diabetes | $2,827 | -7% |
Levemir | diabetes | $2,421 | -10% |
Human insulins | diabetes | $1,572 | -4% |
NovoMix | diabetes | $1,485 | -9% |
Norditropin | HGH deficiency | $1,243 | 9% |
As the prevalence of diabetes has grown in the U.S. and around the world, so too has the demand for effective treatments. In response, Novo Nordisk, the Denmark-based diabetes giant, made two major expansion announcements in 2016. First, in April, it unveiled plans to invest more than $110 million in production facilities at its site in Chartres, France, in an effort to meet the increasing worldwide demand for its diabetes medicines.
The new facilities will be built on Novo Nordisk’s existing 31,000 square-meter site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, the world’s most widely used insulin injection device. The products are exported to more than 40 countries all over the world.
Novo Nordisk has invested nearly $350 million in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years.
Also, in March, the company began construction of a new mega $1.8 billion production facility in Clayton, NC, that will produce active pharmaceutical ingredients (API) for a range of the company’s current and future GLP-1 and insulin products. When fully operational in 2020, the site will take on production capacity for diabetes care products in the U.S. Once complete, the new facility will measure 833,000 square feet and have a footprint of 417,639 square feet—the equivalent to approximately seven football fields.
The new site is situated adjacent to Novo Nordisk’s current 457,000 square foot facility. Expanded several times since it was inaugurated in 1996, Novo Nordisk’s current plant in Clayton is one of the company’s strategic production sites responsible for formulation, filling and packaging of diabetes medicines. The plant also assembles and packages the company’s FlexPen and FlexTouch prefilled insulin devices for the U.S. market.
Once the new site becomes operational, the diabetes API production organization in Clayton will be named DAPI-US (Diabetes Active Pharmaceutical Ingredients–US). It will be part of the Danish diabetes API production organization in Kalundborg, which will be named DAPI-Denmark.
Back in August 2015, Novo Nordisk laid out plans to invest $2 billion into production facilities in Clayton; Malov, Denmark; and Kalundborg, Denmark, with $1.8 billion of this amount being invested in the Clayton plant. That same day, the company announced a decision to initiate Phase III development of oral semaglutide, a GLP-1 analogue formulated as a once-daily tablet for the treatment of type 2 diabetes.